Clinical trials: Stage I Multiple Myeloma
Cancer
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic stem cell transplantation.
- Trial name
- NCT00079222
- Testing
- itraconazole, voriconazole
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Relapsed or Refractory Multiple Myeloma
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT02099539
- Testing
- N-803
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Altor BioScience
Myeloma
Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma
This phase I/II trial studies the side effects and best dose of clarithromycin when given together with ixazomib citrate, pomalidomide, and dexamethasone and to see how well it works in treating patients with multiple myeloma…
- Trial name
- NCT02542657
- Testing
- Clarithromycin, Dexamethasone, Ixazomib Citrate
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Joseph Tuscano
B-Cell Lymphoma, Myelodysplastic Syndromes (MDS)
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma.
- Conditions
- B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma
- Trial name
- NCT05092451
- Testing
- Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
This is a multicenter, open-label, dose-escalation study of MFGR1877S in patients with relapsed or refractory t(4;14)-positive multiple myeloma.
- Trial name
- NCT01122875
- Testing
- MFGR1877S
- Where
- 12 sites in United States, Canada
- Volunteers
- 14 people
- Sponsor
- Genentech, Inc.
Refractory Multiple Myeloma
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01049945
- Testing
- bendamustine hydrochloride, lenalidomide, dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
The purpose of this study is to test the effect of the combination of bortezomib and tipifarnib. Bortezomib (VELCADE) is approved by the Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have…
- Trial name
- NCT00972712
- Testing
- Bortezomib and Tipifarnib
- Where
- 3 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- Emory University
Multiple Myeloma
Hypofractionation (Radiation) Trial for Multiple Myeloma
This study if for people who have been diagnosed with multiple myeloma and their doctors are recommending radiation to help treat it. Typically, radiation consists of 2-3 weeks of external beam radiation therapy.
- Trial name
- NCT06270888
- Testing
- Radiation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Plasma Cell Myeloma
Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma
This phase I trial studies the side effects and best dose of 211At-OKT10-B10 when given together with melphalan before a stem cell transplantation in treating patients with multiple myeloma.
- Trial name
- NCT04466475
- Testing
- Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Melphalan, Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Beta Alethine in Treating Patients With Myeloma
RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00006466
- Testing
- beta alethine
- Where
- 3 sites in United States
- Sponsor
- LifeTime Pharmaceuticals
Multiple Myeloma and Plasma Cell Neoplasm
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004072
- Testing
- O6-benzylguanine, carmustine
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma.
- Trial name
- NCT04822337
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Wake Forest University Health Sciences
Refractory Multiple Myeloma
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as azacitidine and dexamethasone, work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01155583
- Testing
- azacitidine, lenalidomide, dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Case Comprehensive Cancer Center
Myeloma, Multiple
CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma
This study is to determine the maximum tolerated dose(MTD), dose limiting toxicity(DLT), safety and pharmacokinetics(PK) profile of a single agent CKD-581 injection in Combination with Bortezomib and Dexamethasone in patients…
- Trial name
- NCT03051841
- Testing
- CKD-581
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Multiple Myeloma and Plasma Cell Neoplasm
Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy such as brostallicin use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00060203
- Testing
- brostallicin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
This phase I trial is studying how well ipilimumab works after allogeneic stem cell transplant in treating patients with persistent or progressive cancer.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00060372
- Testing
- ipilimumab, therapeutic allogeneic lymphocytes
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Plasma Cell Leukemia in Remission, Plasma Cell Myeloma
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
This phase I/II trial studies the side effects and best dose of melphalan and total marrow irradiation and how well they work with autologous stem cell transplantation in treating patients with high-risk multiple myeloma.
- Trial name
- NCT03100877
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim
- Where
- United States
- Sponsor
- City of Hope Medical Center
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone).
- Conditions
- Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
- Trial name
- NCT04566328
- Testing
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone
- Where
- 647 sites in United States, Puerto Rico
- Volunteers
- 1,450 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Multiple Myeloma
NMP in Relapsed / Refractory Myeloma
The study will evaluate if the N-methyl-pyrrolidone (NMP) can be safely administered to humans at doses, which induce measurable immunological and anti-tumour effects in patients with myeloma who are resistant to or intolerant of…
- Trial name
- NCT02468687
- Testing
- N-methyl-pyrrolidone
- Where
- Australia
- Volunteers
- 13 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Multiple Myeloma
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
This is a Phase I, open-label, multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide, dexamethasone, and intravenous SGN-40 in patients with relapsed multiple myeloma.
- Trial name
- NCT00525447
- Testing
- SGN-40, lenalidomide, dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Seagen Inc.